The correct name for White Blood Boosting Injection is Recombinant Human Granulocyte Colony Stimulating Factor for Injection, and its side effects commonly include bone pain, back pain, headache, high fever, and rash, with the short-acting injection lasting 2 days and the long-acting injection lasting 2 weeks. Recombinant Human Granulocyte Colony Stimulating Factor for Injection, its active ingredient is Recombinant Human Granulocyte Colony Stimulating Factor, which works by stimulating bone marrow hematopoiesis to continuously produce white blood cells. Side effects of this product are commonly bone pain, back pain, headache, high fever, skin rash, sometimes accompanied by nausea, vomiting, diarrhea, hair loss, etc. For the older, frail or chronically ill, recombinant human granulocyte colony-stimulating factor for injection should be given as early as possible after chemotherapy to reduce the chance of infection. This product is contraindicated in patients with allergic reactions to this preparation or other granulocyte-stimulating factor preparations, in patients with myeloid leukemia who do not have adequate reduction of naïve cells in the bone marrow, and in patients with myeloid leukemia in whom naïve cells are confirmed in the peripheral blood, in patients with the potential to increase naïve cells, and in patients with severe hepatic, renal, cardiac, or pulmonary dysfunction. Recombinant Human Granulocyte Colony Stimulating Factor for Injection is divided into short-acting and long-acting injections based on the duration of action, which lasts for 2 days and 2 weeks, respectively, so the side effects slowly disappear after the drug has worn off. Whether cancer patients need to use recombinant human granulocyte colony-stimulating factor for injection should be judged according to the severity of the disease and the risk of complications. It is recommended to consult a regular hospital, follow the doctor’s instructions to choose the appropriate drug treatment and closely observe the side effects.